Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS
- Sponsors Genentech
- 07 Jan 2016 Results of pooled analysis of seven studies published in the Journal of Thoracic Oncology
- 07 Oct 2013 Status changed from active, no longer recruiting to completed according to results published in the Journal of Clinical Oncology.
- 11 Dec 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.